<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="440">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155423</url>
  </required_header>
  <id_info>
    <org_study_id>PA18-0190</org_study_id>
    <nct_id>NCT05155423</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy</brief_title>
  <official_title>Best Practice of MRI Simulation in Spinal Stereotactic Body Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elekta Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To learn the usefulness of performing MRI scans in different positions and learn the best&#xD;
      practice for spinal stereotactic body radiation therapy (spinal SBRT) planning and dose&#xD;
      delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Objectives&#xD;
&#xD;
        1. Assess the feasibility of performing MRI scans in the treatment position for accurate&#xD;
           treatment planning and dose delivery in spinal stereotactic body radiation therapy&#xD;
           (spinal SBRT).&#xD;
&#xD;
        2. Characterize the improved accuracy of image fusion between MRI and CT and its dosimetric&#xD;
           impact when performing MRI scans in treatment position in spinal SBRT.&#xD;
&#xD;
        3. Assess the ability of MRI simulation to accurately target extended spinal targets beyond&#xD;
           the current targeting limitations (&gt;3 consecutive vertebral body levels)&#xD;
&#xD;
        4. Optimize the workflow of using MRI simulation in treatment planning and dose delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 21, 2018</start_date>
  <completion_date type="Anticipated">April 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>performing MRI scans in the treatment position for accurate treatment planning.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Performing MRI scans in the treatment position for dose delivery in spinal stereotactic body radiation therapy (spinal SBRT).</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Spinal Metastases</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>patient using mask for immobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <description>patients using Elekta BodyFix</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mask for immobilization</intervention_name>
    <description>mask for immobilization</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elekta BodyFix</intervention_name>
    <description>Elekta BodyFix</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MDACC Cancer Participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        3.1. Inclusion Criteria&#xD;
&#xD;
          1. Greater than or equal to 18 years of age&#xD;
&#xD;
          2. Pathologically confirmed diagnosis of cancer, including, but not limited to non-small&#xD;
             cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma,&#xD;
             thyroid, head and neck primary, and carcinoma of unknown primary&#xD;
&#xD;
          3. Signed informed consent&#xD;
&#xD;
          4. Willing to undergo 2 MRI simulations in one or multiple sessions, one with&#xD;
             immobilization device, and the other without.&#xD;
&#xD;
          5. Patients undergoing spinal SBRT 3.2. Exclusion Criteria&#xD;
&#xD;
        a. Patient with a relative or absolute contraindication to MRI (such as pacemaker, etc.) b.&#xD;
        Patients with significant instrumentation or cement at the site of interest causing&#xD;
        artifact c. Inability to tolerate with immobilization device for greater than 30 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amol Ghia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

